Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global AI medical ...

PHILADELPHIA, PA, UNITED STATES, January 29, 2026 /EINPresswire.com/ -- Ahead of Black History Month, AVI$U—an ...

The enterprise shift toward distributed systems of specialized AI agents is happening because reality is complex, and when ...

Ricursive Intelligence, a frontier AI lab founded by the co-creators of AlphaChip, today announced a $300 million Series A funding round led by Lightspeed Venture Partners at a $4 billion post-money ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

The latest edition of the International Energy Agency’s (IEA) World Energy Employment report found employment in the PV sector surpassed 5 million in 2024, with distributed solar accounting for ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...